To fully appreciate the totality of Ad.tCCN1-CTV-m7 properties as a gene therapeutic vector, which include direct oncolysis, anti-tumor MDA-7/IL-24 effects via direct cancer cell apoptosis and through potent ‘bystander antitumor effects’ [10, 15, 16, 43], as well as involvement of components of the immune system [44, 45], it is essential to validate efficacy in an immune-competent CaP animal model, such as the Hi-myc mouse [46]. The gene discussed is IL24; the disease is cancer.